Identification of Apo-A1 as a biomarker for early diagnosis of bladder transitional cell carcinoma

Li, Hongjie; Li, Changying; Wu, Huili; Zhang, Tingting; Wang, Jinjin; Wang, Shixin; Chang, Jie

doi:10.1186/1477-5956-9-21

Cited by 73 publications

(49 citation statements)

References 35 publications

(45 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Apolipoprotein A-I peptide fragments were found up-regulated in both primary and recurrent disease in line with earlier reported findings on this protein in urothelial bladder cancer following application of two-dimensional electrophoresis (2-DE), or iTRAQ/LC-MS/MS-based proteomics analysis (28)(29)(30)(31)(32)(33)(34)(35). In addition, Fibrinogen chains a and b, well known urinary biomarkers for the detection of bladder cancer (30,31,(33)(34)(35), were also found at increased levels in urine from patients with urothelial bladder cancer and included in the classifiers. Beta-2-macroglobulin and basement membrane-specific heparan sulfate proteoglycan core protein (HSPG2) were also confirmed with decreased excretion levels in urine from patients with urothelial bladder cancer, in line with previously reported proteomics data (28,31,33).…”

Section: Discussionsupporting

confidence: 74%

Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study

Frantzi

Kessel

Zwarthoff

et al. 2016

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Urothelial bladder cancer presents high recurrence rates, mandating continuous monitoring via invasive cystoscopy. The development of noninvasive tests for disease diagnosis and surveillance remains an unmet clinical need. In this study, validation of two urine-based biomarker panels for detecting primary and recurrent urothelial bladder cancer was conducted.Experimental Design: Two studies (total n ¼ 1,357) were performed for detecting primary (n ¼ 721) and relapsed urothelial bladder cancer (n ¼ 636). Cystoscopy was applied for detecting urothelial bladder cancer, while patients negative for recurrence had follow-up for at least one year to exclude presence of an undetected tumor at the time of sampling. Capillary electrophoresis coupled to mass spectrometry (CE-MS) was employed for the identification of urinary peptide biomarkers. The candidate urine-based peptide biomarker panels were derived from nested cross-sectional studies in primary (n ¼ 451) and recurrent (n ¼ 425) urothelial bladder cancer.Results: Two biomarker panels were developed on the basis of 116 and 106 peptide biomarkers using support vector machine algorithms. Validation of the urine-based biomarker panels in independent validation sets, resulted in AUC values of 0.87 and 0.75 for detecting primary (n ¼ 270) and recurrent urothelial bladder cancer (n ¼ 211), respectively. At the optimal threshold, the classifier for detecting primary urothelial bladder cancer exhibited 91% sensitivity and 68% specificity, while the classifier for recurrence demonstrated 87% sensitivity and 51% specificity. Particularly for patients undergoing surveillance, improved performance was achieved when combining the urine-based panel with cytology (AUC ¼ 0.87).Conclusions: The developed urine-based peptide biomarker panel for detecting primary urothelial bladder cancer exhibits good performance. Combination of the urine-based panel and cytology resulted in improved performance for detecting disease recurrence.

show abstract

Section: Discussionsupporting

confidence: 74%

Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study

Frantzi

Kessel

Zwarthoff

et al. 2016

Clinical Cancer Research

View full text Add to dashboard Cite

show abstract

“…In 2013, a point-of-care device was presented for bladder cancer diagnosis based on magnetic microbead capture of apolipoprotein A1 (APOA1) [77], which has been demonstrated to be present at elevated concentrations in the urine of bladder cancer patients [99][100][101] (Figure 4). Magnetic microbeads bound to APOA1-targeted antibodies were incubated with a urine sample to allow binding of APOA1 to the microbead.…”

Section: Antibody-bonded Substratesmentioning

confidence: 99%

Microdevices for Non-Invasive Detection of Bladder Cancer

et al. 2017

View full text Add to dashboard Cite

Bladder cancer holds the record for the highest lifetime cost on a per-patient basis. This is due to high recurrence rates, which necessitate invasive and costly long-term evaluation methods such as cystoscopy and imaging. Microfluidics is emerging as an important approach to contribute to initial diagnosis and follow-up, by enabling the precise manipulation of biological samples. Specifically, microdevices have been used for the isolation of cells or genetic material from blood samples, sparking significant interest as a versatile platform for non-invasive bladder cancer detection with voided urine. In this review, we revisit the methods of bladder cancer detection and describe various types of markers currently used for evaluation. We detail cutting-edge technologies and evaluate their merits in the detection, screening, and diagnosis of bladder cancer. Advantages of microscale devices over standard methods of detection, as well as their limitations, are provided. We conclude with a discussion of criteria for guiding microdevice development that could deepen our understanding of prognoses at the level of individual patients and the underlying biology of bladder cancer development. Collectively, the development and widespread application of improved microfluidic devices for bladder cancer could drive treatment breakthroughs and establish widespread, tangible outcomes on patients' long-term survival.

show abstract

“…1,2 If the abnormal tissue or tumor is identified early, treatment and recovery may be easier. The standard method for the clinical detection of bladder cancer is cytology, which shows low sensitivity for low-grade bladder cancers.…”

Section: Introductionmentioning

confidence: 99%

“…The standard method for the clinical detection of bladder cancer is cytology, which shows low sensitivity for low-grade bladder cancers. [1][2][3] Cystoscopy is frequently used to examine and monitor patients for the recurrence or progression of this disease. However, this detection method is invasive and expensive.…”

Section: Introductionmentioning

confidence: 99%

“…Recently, apolipoprotein A1 (APOA1) has been identified as a potential biomarker that can be used for the early diagnosis of bladder cancer. 1,6,7 Enzyme-linked immunosorbent assay (ELISA), a high-sensitivity technique, is the current standard method for the quantitative analysis of a target protein in biological samples. The amounts of certain proteins in urine samples have been suggested to be reliable and quantitative indicators of bladder cancer.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

A negative-pressure-driven microfluidic chip for the rapid detection of a bladder cancer biomarker in urine using bead-based enzyme-linked immunosorbent assay

et al. 2013

View full text Add to dashboard Cite

This paper describes an integrated microfluidic chip that is capable of rapidly and quantitatively measuring the concentration of a bladder cancer biomarker, apolipoprotein A1, in urine samples. All of the microfluidic components, including the fluid transport system, the micro-valve, and the micro-mixer, were driven by negative pressure, which simplifies the use of the chip and facilitates commercialization. Magnetic beads were used as a solid support for the primary antibody, which captured apolipoprotein A1 in patients' urine. Because of the three-dimensional structure of the magnetic beads, the concentration range of the target that could be detected was as high as 2000 ng ml À1 . Because this concentration is 100 times higher than that quantifiable using a 96-well plate with the same enzyme-linked immunosorbent assay (ELISA) kit, the dilution of the patient's urine can be avoided or greatly reduced. The limit of detection was determined to be approximately 10 ng ml À1 , which is lower than the cutoff value for diagnosing bladder cancer (11.16 ng ml À1 ). When the values measured using the microfluidic chip were compared with those measured using conventional ELISA using a 96-well plate for five patients, the deviations were 0.9%, 6.8%, 9.4%, 1.8%, and 5.8%. The entire measurement time is 6-fold faster than that of conventional ELISA. This microfluidic device shows significant potential for point-ofcare applications. V C 2013 American Institute of Physics.

show abstract

Identification of Apo-A1 as a biomarker for early diagnosis of bladder transitional cell carcinoma

Cited by 73 publications

References 35 publications

Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study

Development and Validation of Urine-based Peptide Biomarker Panels for Detecting Bladder Cancer in a Multi-center Study

Microdevices for Non-Invasive Detection of Bladder Cancer

A negative-pressure-driven microfluidic chip for the rapid detection of a bladder cancer biomarker in urine using bead-based enzyme-linked immunosorbent assay

Contact Info

Product

Resources

About